Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.

Core Viewpoint - Eli Lilly has seen a significant increase of 47% in its stock price this year, prompting investors to seek alternative opportunities in the biotech sector, particularly companies developing weight loss drugs [1] Group 1: Viking Therapeutics - Viking Therapeutics has multiple upcoming data readouts that are expected to significantly impact its share price, particularly from its obesity-related clinical trials for VK2735 [2] - The phase 2 trial for the injectable version of VK2735 has been completed successfully, and the company is awaiting FDA assessment for a phase 3 trial [3] - VK2735 has shown promising results, with patients losing an average of approximately 13% of their body mass after 13 weeks of treatment, potentially outperforming existing market leaders like Eli Lilly's Mounjaro and Novo Nordisk's Wegovy [3][4] - The timeline for the phase 3 trial's conclusion remains unclear, but it is estimated to be within a couple of years [4] - The oral formulation of VK2735 has completed phase 1 trials, with phase 2 trials expected to start later this year, indicating potential for further stock movement [4] Group 2: Structure Therapeutics - Structure Therapeutics is also targeting the cardiometabolic therapy market with its candidate GSBR-1290, which is designed for weight loss and is formulated as a pill [6] - The phase 2a trials for GSBR-1290 have shown promising results, with patients experiencing a placebo-adjusted average weight loss of just over 6% over 12 weeks [6] - Phase 2b trials are anticipated to begin in the fourth quarter, with data expected to be released at various points in 2025, providing insights into the candidate's long-term efficacy and safety [7] - The phase 2b trial will last three times longer than the previous phase, increasing the stakes for Structure Therapeutics [7] - There is a risk that if the larger data set does not compare favorably to existing products, it could negatively impact the stock, despite the trials being deemed successful [8]